TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) : Traders are bullish on TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) as it has outperformed the S&P 500 by a wide margin of 12.13% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.06%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.41% in the last 1 week, and is up 13.94% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -88.24% from its 1 Year high price. On Jul 13, 2015, the shares registered one year high at $3.09 and the one year low was seen on Feb 25, 2016. The 50-Day Moving Average price is $0.32 and the 200 Day Moving Average price is recorded at $0.34.
The stock has recorded a 20-day Moving Average of 3.36% and the 50-Day Moving Average is 9.47%.
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG): On Fridays trading session , Opening price of the stock was $0.36 with an intraday high of $0.37. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.304. However, the stock managed to close at $0.3303, a loss of 8.25% for the day. On the previous day, the stock had closed at $0.36. The total traded volume of the day was 813,860 shares.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Tetralogic Pharmaceuticals Corp, Pecora Andrew L, had purchased 50,000 shares in a transaction dated on July 10, 2015. The transaction was executed at $2.66 per share with total amount equaling $133,000.
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company engaged in discovering and developing small molecule therapeutics in oncology and infectious diseases. The Company has two clinical-stage product candidates: birinapant and suberohydroxamic acid 4-methoxycarbonyl phenyl ester (SHAPE). Birinapant is a small molecule therapeutic that mimics second mitochondrial activator of caspases (SMAC-mimetic). Birinapant is in a Phase II clinical trial for the treatment of myelodysplastic syndromes (MDS), a Phase I/II clinical trial for third-line ovarian cancer and a Phase I clinical trial for the treatment of chronic human hepatitis B virus (HBV). The Company has completed a Phase I/II clinical trial of birinapant in acute myeloid leukemia (AML), MDS and acute lymphocytic leukemia (ALL). SHAPE is a histone deacetylase (HDAC) inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL) and is in Phase II clinical trial stage.